GlaxoSmithKline is recalling supplies of its OTC weight-loss drug alli in light of reports from U.S. consumers who found the wrong drug when they opened their bottles.
European officials gave a green light to GlaxoSmithKline's once-weekly diabetes drug Eperzan (albiglutide). The GLP-1 drug is awaiting FDA approval, with a decision expected next month.
Merck and GlaxoSmithKline have nixed their copay assistance for Obamacare patients. The two companies say they fear subsidizing patients' drug purchases will run afoul of federal anti-kickbacks law. But many other top drugmakers- including Novartis, Sanofi and Eli Lilly--will keep their copay cards and discounts, at least for now.
Translating all the information from the genomics revolution into verifiable drug targets has proven to be no easy task. Now, in an effort to bend the curve toward R&D success, GlaxoSmithKline is teaming up with external experts, putting up money and brainpower to launch a collaborative research effort.
GlaxoSmithKline announced today that bottles of its alli over-the-counter weight-loss drug were tampered with, and warned consumers to look out for suspect packages.
Some U.S. consumers found the wrong drug when they opened their packages of alli, the GlaxoSmithKline weight-loss pill, the company said. Glaxo is warning alli users to check their packages carefully and avoid taking any pills that might not be authentic.
The FDA may have given its blessing to GlaxoSmithKline's melanoma combo Tafinlar and Mekinist. But not so fast, says its counterpart across the pond. The European Medicines Agency (EMA) wants more information, and that has prompted GSK to withdraw its application--for now.
With its PDUFA date for the once-weekly diabetes drug albiglutide looming at the FDA next month, GlaxoSmithKline announced today that the European Commission has OK'd the GLP-1 drug for marketing.
Last month GlaxoSmithKline CEO Andrew Witty gave an upbeat assessment of the prospects of the MAGE-A3 cancer vaccine, with the executive saying the product has several chances to succeed. Now it has one fewer after the vaccine missed its primary endpoints in a Phase III lung cancer trial.
How do you halve the time it takes for GlaxoSmithKline toothpaste makers to change over their lines? Reenvision the production line as an F1 racetrack, according to McLaren.